MedPath

Tranilast

Generic Name
Tranilast
Drug Type
Small Molecule
Chemical Formula
C18H17NO5
CAS Number
53902-12-8
Unique Ingredient Identifier
HVF50SMY6E
Background

Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Indication

For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Clinical Trials
Related News

Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia

Early Phase 1
Not yet recruiting
Conditions
Prostatic Hypertrophy, Benign
Interventions
Drug: alpha receptor antagonist
First Posted Date
2024-11-14
Last Posted Date
2024-11-14
Lead Sponsor
Yifeng Jing
Target Recruit Count
30
Registration Number
NCT06689514
Locations
🇨🇳

Shanghai General Hospital, Shanghai, China

Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms

Phase 2
Not yet recruiting
Conditions
Esophageal Stricture
Esophageal Neoplasms
Interventions
First Posted Date
2024-10-16
Last Posted Date
2024-11-14
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
394
Registration Number
NCT06643689
Locations
🇨🇳

Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China

🇨🇳

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

🇨🇳

Shaoxing Central Hospital, Shaoxing, Zhejiang, China

Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea

Phase 4
Conditions
Rosacea
Interventions
First Posted Date
2024-03-12
Last Posted Date
2024-03-12
Lead Sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Target Recruit Count
45
Registration Number
NCT06307288
Locations
🇨🇳

The Second Affiliated Hospital of Xi'an Jiaotong Universi, Xi'an, Shaanxi, China

Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Phase 2
Recruiting
Conditions
Nasopharyngeal Carcinoma
Recurrent Cancer
Interventions
First Posted Date
2022-11-25
Last Posted Date
2023-10-06
Lead Sponsor
Jian Guan
Target Recruit Count
18
Registration Number
NCT05626829
Locations
🇨🇳

Southern medical university, Guangzhou, Guangdong, China

Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI

Phase 4
Completed
Conditions
NLRP3
Percutaneous Coronary Intervention
hsCRP
Interventions
First Posted Date
2021-11-23
Last Posted Date
2023-02-08
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
132
Registration Number
NCT05130892
Locations
🇨🇳

Wuhan Union Hospital, Wuhan, Hubei, China

🇨🇳

Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)

Phase 2
Recruiting
Conditions
Cryopyrin-Associated Periodic Syndromes
Interventions
First Posted Date
2019-04-22
Last Posted Date
2019-06-04
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
71
Registration Number
NCT03923140
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

A Clinical Study of Tranilast in the Treatment of Sarcoidosis

Early Phase 1
Conditions
Sarcoidosis
Interventions
First Posted Date
2018-05-17
Last Posted Date
2018-05-17
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
56
Registration Number
NCT03528070

A Clinical Study of Tranilast in the Treatment of Scleredema Diabeticorum

Early Phase 1
Conditions
Scleredema Adultorum
Interventions
First Posted Date
2018-05-01
Last Posted Date
2018-05-01
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
56
Registration Number
NCT03512873

A Clinical Study of Tranilast in the Treatment of Mucinoses

Early Phase 1
Conditions
Mucinoses
Interventions
First Posted Date
2018-04-06
Last Posted Date
2018-04-06
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
56
Registration Number
NCT03490708

Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia

Phase 2
Completed
Conditions
Gout
Hyperuricemia
Interventions
Drug: High dose combination
First Posted Date
2010-01-21
Last Posted Date
2011-01-06
Lead Sponsor
Nuon Therapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT01052987
Locations
🇺🇸

Nuon Investigative Site, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy